Matches in Wikidata for { <http://www.wikidata.org/entity/Q92607491> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q92607491 description "artículu científicu espublizáu en xunu de 2019" @default.
- Q92607491 description "scientific article published on 26 June 2019" @default.
- Q92607491 description "wetenschappelijk artikel" @default.
- Q92607491 description "наукова стаття, опублікована 26 червня 2019" @default.
- Q92607491 name "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 name "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 type Item @default.
- Q92607491 label "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 label "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 prefLabel "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 prefLabel "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 P1433 Q92607491-2881B889-65FE-45CD-8FC8-BA26C532E5A1 @default.
- Q92607491 P1476 Q92607491-0B07E53D-6FFF-487B-A741-81A4B5D88899 @default.
- Q92607491 P2093 Q92607491-077ECBA6-AB78-4339-A0D4-1AB11C546885 @default.
- Q92607491 P2093 Q92607491-36D4F2D5-6F42-4B3F-84B1-6C0CBB2D0213 @default.
- Q92607491 P2093 Q92607491-3B1FDCE3-5083-42A0-A8BC-700256F11AEF @default.
- Q92607491 P2093 Q92607491-5E38C7ED-68BD-4FBF-B718-60DAC4346D09 @default.
- Q92607491 P2093 Q92607491-6757FEFF-A909-4DB8-835E-E4098C96E5B2 @default.
- Q92607491 P2093 Q92607491-8ACB5ED8-29A9-4D25-A858-48BBEC87A4F5 @default.
- Q92607491 P2093 Q92607491-93EB2E9F-9722-4662-B445-2685C377BFF3 @default.
- Q92607491 P2093 Q92607491-BCACC2C1-FD1D-496D-A2BF-C4EA14AFFBB0 @default.
- Q92607491 P2093 Q92607491-D57FE9AC-341F-48EB-AC9D-3F882438D016 @default.
- Q92607491 P2093 Q92607491-E164D916-451B-4071-9AB9-E39F88A98682 @default.
- Q92607491 P2093 Q92607491-FAFD43CA-57A0-47AC-A6BF-CC1FC2C3909F @default.
- Q92607491 P31 Q92607491-CB8012D8-F897-46D0-9CB4-FB204F702A49 @default.
- Q92607491 P356 Q92607491-1E22093C-267A-45F1-8CF7-9D0648AFE32D @default.
- Q92607491 P50 Q92607491-7CCF586C-ACB7-409E-B298-758E84B201A5 @default.
- Q92607491 P577 Q92607491-02F4C2B5-C6E6-4BE7-B242-ED3BE5A49E9B @default.
- Q92607491 P698 Q92607491-6440B7FC-AA27-4BFF-90CA-45DCEEE240EF @default.
- Q92607491 P356 J.CLBC.2019.06.005 @default.
- Q92607491 P698 31932237 @default.
- Q92607491 P1433 Q332245 @default.
- Q92607491 P1476 "A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer" @default.
- Q92607491 P2093 "Aurelio Castrellon" @default.
- Q92607491 P2093 "Bertrand Anz" @default.
- Q92607491 P2093 "Brian Hemphill" @default.
- Q92607491 P2093 "Howard A Burris" @default.
- Q92607491 P2093 "John D Hainsworth" @default.
- Q92607491 P2093 "Laura Blakely" @default.
- Q92607491 P2093 "Laura M DeBusk" @default.
- Q92607491 P2093 "Mark Mainwaring" @default.
- Q92607491 P2093 "Mythili Shastry" @default.
- Q92607491 P2093 "Robyn R Young" @default.
- Q92607491 P2093 "William Liggett" @default.
- Q92607491 P31 Q13442814 @default.
- Q92607491 P356 "10.1016/J.CLBC.2019.06.005" @default.
- Q92607491 P50 Q89724740 @default.
- Q92607491 P577 "2019-06-26T00:00:00Z" @default.
- Q92607491 P698 "31932237" @default.